Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and β-Cell Function in TODAY

June 2013
Diabetes Care;Jun2013, Vol. 36 Issue 6, p1749
Academic Journal
OBJECTIVE--The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial demonstrated that combination therapy with metformin plus rosiglitazone provided superior durability of glycemic control compared with metformin alone, with significantly lower treatment failure rates (38.6 vs. 51.7%), and metformin plus lifestyle was intermediate. Herein we describe the temporal changes in measures of β-cell function and insulin sensitivity over a 4-year period among the three treatments. RESEARCH DESIGN AND METHODS--TODAY participants (699) were tested periodically with an oral glucose tolerance test to determine insulin sensitivity (1/fasting insulin [1/IF]), insulinogenic index (ΔI30/ΔG30) or C-peptide index (ΔC30/ΔG30), and β-cell function relative to insulin sensitivity (oral disposition index [oDI]). RESULTS--During the first 6 months, metformin plus rosiglitazone exhibited a significantly greater improvement in insulin sensitivity and oDI versusmetformin alone and versus metformin plus lifestyle; these improvements were sustained over 48 months of TODAY. Irrespective of treatment, those who failed to maintain glycemic control had significantly lower β-cell function (~50%), higher fasting glucose concentration, and higher HbA1c at randomization compared with those who did not fail. CONCLUSIONS--The beneficial change in insulin sensitivity and the resultant lower burden on β-cell function achieved in the first 6 months with metformin plus rosiglitazone appear to be responsible for its superior glycemic durability over metformin alone and metformin plus lifestyle. However, initial β-cell reserve and HbA1c at randomization are independent predictors of glycemic durability. Therefore, efforts to preserve β-cell function before significant loss occurs and to reduce HbA1c may be beneficial in the treatment of youth with type 2 diabetes.


Related Articles

  • Safety and Tolerability of the Treatment of Youth-Onset Type 2 Diabetes.  // Diabetes Care;Jun2013, Vol. 36 Issue 6, p1765 

    OBJECTIVE--Data related to the safety and tolerability of treatments for pediatric type 2 diabetes are limited. The TODAY clinical trial assessed severe adverse events (SAEs) and targeted nonsevere adverse events (AEs) before and after treatment failure, which was the primary outcome (PO)....

  • A novel fast-slow model of diabetes progression: Insights into mechanisms of response to the interventions in the Diabetes Prevention Program. De Gaetano, Andrea; Hardy, Thomas Andrew // PLoS ONE;10/10/2019, Vol. 14 Issue 10, p1 

    Several models for the long-term development of T2DM already exist, focusing on the dynamics of the interaction between glycemia, insulinemia and β-cell mass. Current models consider representative (fasting or daily average) glycemia and insulinemia as characterizing the compensation state of...

  • Safety and Efficacy of Pioglitazone/Metformin Combination Therapy in Treatment of Type 2 Diabetes: A Rationale for Earlier Use. Stolar, Mark // Clinical Medicine: Therapeutics;2009, Issue 1, p289 

    Although multiple new agents for the management of diabetes have become available in the past decade, less than 50% of diabetics in the United States have Hgb A-1-C levels below 7.0% and far fewer at the newer more stringent targets of 6.0% to 6.5%. It has become increasingly clear that the...

  • The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study. Moon, Jun; Ha, Kyoung; Yoon, Ji; Lee, Hyoung; Lee, Hyun; Won, Kyu // Acta Diabetologica;Apr2014, Vol. 51 Issue 2, p277 

    The aim of present study is to assess whether if basal insulin, glargine, could improve insulin secretory function of β-cells compared with glimepiride when metformin alone was failed. This was an open-label and multi-center study for 52 weeks in Korean patients with uncontrolled type 2...

  • Plasma Glucose Concentration and Prediction of Future Risk of Type 2 Diabetes. Abdul-Ghani, Muhammad A.; DeFronzo, Ralph A. // Diabetes Care;Nov2009 Supplement, Vol. 32, pS194 

    The article examines the effectiveness of several prediction models for type 2 diabetes in identifying patients susceptible to the disease based on several studies. Epidemiological studies revealed that patients who developed type 2 diabetes had normal glucose tolerance, challenging impaired...

  • Two-Hour Seven-Sample Oral Glucose Tolerance Test and Meal Protocol. Man, Chiara Dalla; Campioni, Marco; Polonsky, Kenneth S.; Basu, Rita; Rizza, Robert A.; Toffolo, Gianna; Cobelli, Claudio // Diabetes;Nov2005, Vol. 54 Issue 11, p3265 

    Highly informative yet simple protocols to assess insulin secretion and action would considerably enhance the quality of epidemiological and large-scale clinical trials. In an effort to develop such protocols, a 5-h, 11-sample oral glucose tolerance test (OGTT) was performed in 100 individuals...

  • Metabolic disorders: Betatrophin boosts β-cells. Crunkhorn, Sarah // Nature Reviews Drug Discovery;Jul2013, Vol. 12 Issue 7, p504 

    The article discusses research being done on a novel liver-secreted hormone called betatrophin. It references a study by P. Yi et al published in a 2013 issue of "Cell."According to the study, an adult mice infused with a 43-amino-acid peptide showed glucose intolerance, insulin resistance,...

  • Is the Disposition Index Law Hyperbolic? Importance of the Regression Methodology. Denti, Paolo; Campioni, Marco; Toffolo, Gianna Maria; Rizza, Robert; Cobelli, Claudio // Diabetes;Jun2007 Supplement 1, Vol. 56, pA664 

    The article focuses on a study that aims to test the validity of the Hyperbolic Law Disposition Index (DI). It states that glucose and C-peptide minimal models were interpreted to IVGTT in elderly subjects to estimate insulin sensitivity and beta-cell responsivity. It mentions that linear...

  • Use and abuse of HOMA modeling. Wallace, Tara M.; Levy, Jonathan C.; Matthews, David R. // Diabetes Care;Jun2004, Vol. 27 Issue 6, p1487 

    Homeostatic model assessment (HOMA) is a method for assessing beta-cell function and insulin resistance (IR) from basal (fasting) glucose and insulin or C-peptide concentrations. It has been reported in >500 publications, 20 times more frequently for the estimation of IR than beta-cell function....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics